CRBP COO sells 2,415 shares in tax-cover trade

Corbus Pharmaceuticals Holdings, Inc. Chief Operating Officer Ian Hodgson reported a mandated sale of common stock.

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. Chief Operating Officer Ian Hodgson reported a mandated sale of common stock. On February 3, 2026, he sold 2,415 shares of Corbus common stock at a weighted average price of $8.0899 per share to cover tax withholding from vesting restricted stock units (RSUs).

The company required this "sell to cover" transaction for tax obligations, so it was not a discretionary trade by Hodgson. After the sale, he beneficially owned 51,927 shares, which includes 48,108 unvested RSUs that remain subject to their respective vesting schedules.

Insider Trade Summary

Net Seller: 2,415 shares

Net Sell 1 txn

Insider Hodgson Ian

Role Chief Operating Officer

Sold 2,415 shs ($20K)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.0001 per share	2,415	$8.0899	$20K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 51,927 shares (Direct)

Footnotes (3)

1. F1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $8.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. This amount includes 48,108 unvested RSUs subject to each grant's vesting schedule as previously reported.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CRBP’s COO Ian Hodgson report?

Ian Hodgson reported selling 2,415 shares of Corbus common stock. The transaction occurred on February 3, 2026, and was tied to tax withholding from vesting restricted stock units, rather than a discretionary open-market sale decision by the executive.

At what price were Ian Hodgson’s CRBP shares sold in this Form 4 filing?

The reported weighted average sale price was $8.0899 per share. Shares were sold in multiple trades within a price range from $8.01 to $8.15, as disclosed, with detailed breakdowns available upon request from the issuer or the reporting person.

Why did CRBP’s COO sell shares according to this Form 4?

The sale was made to cover tax withholding obligations arising from the vesting and settlement of restricted stock units. Corbus elected to require a "sell to cover" approach, so the transaction was mandated rather than a voluntary stock sale by the chief operating officer.

How many CRBP shares does Ian Hodgson own after the reported transaction?

Following the sale, Ian Hodgson beneficially owned 51,927 shares of Corbus common stock. This total includes 48,108 unvested restricted stock units, which will vest over time according to previously established and disclosed vesting schedules for each RSU grant.

Does this CRBP Form 4 indicate discretionary insider selling by management?

No, the filing states the sale was mandated to satisfy tax withholding on vesting RSUs via a "sell to cover" election. It explicitly notes the transaction does not represent a discretionary stock sale decision by the reporting person, Chief Operating Officer Ian Hodgson.

What additional price information is available for the CRBP insider sale?

The filing notes the $8.0899 figure is a weighted average across multiple trades between $8.01 and $8.15. The reporting person commits to provide full details on the number of shares sold at each specific price within that range upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hodgson Ian

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	02/03/2026		S(1)		2,415	D	$8.0899(2)	51,927(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $8.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This amount includes 48,108 unvested RSUs subject to each grant's vesting schedule as previously reported.

	/s/ Meghan Houghton, attorney-in-fact for Ian Hodgson	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.